William Blair analyst Matt Phipps reiterated an Outperform rating on Insmed (NASDAQ: INSM)The analyst commented, "This morning, Insmed released top-line ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE